The Global. A recent report has quantified the impact that the arrival of biosimilars has had on the pharmaceutical market in terms of access to new therapies, market share and the effect of reducing prices. Specifically, the study is prepared by the specialized consultancy IMS Health for the European Commission and condenses that the introduction of these drugs is democratizing patient access to biological treatments in the European Economic Area (EEA) —EU plus, Norway, Iceland and Liechtenstein.